Preventive (prophylactic) treatment with Wilate reduced annual bleeding rates by more than 80% in people with von Willebrand disease (VWD) type 3, the…
Hetrombopag appears to be a safe and effective option for treating children with immune thrombocytopenia (ITP), with better outcomes linked to younger age and newly diagnosed disease, a study finds. The study findings also highlight that hetrombopag “may serve as a viable option for patients for whom first-line therapy fails,” researchers…
Latest news & perspectives
A recent report describes the case of a woman with acquired thrombotic thrombocytopenic purpura (TTP) who was later found to have an undetected human…
